Anterior ischaemic optic neuropathy (AION), a common, visually crippling dis order, is discussed, with particular emphasis on differentiating AION due to giant cell arteritis (arteritic AION) from that not due to it (non-arteritic AION). Giant cell arteritis is an ophthalmic emergency because of imminent danger of bilateral total blindness, which is almost always preventable if the disease is quickly identified and treated urgently and aggressively. My studies have revealed that the best means of differentiating arteritic from non-arteritic AION is a combination of information from the following: systemic and visual symptoms of giant cell arteritis, high eryth rocyte sedimentation rate and C-reactive protein, early massive visual loss, chalky white optic disc swelling, associated cilio-retinal artery occlusion, massive non-filling of the choroid on fluorescein fundus angiography and temporal artery biopsy.
differentiating arteritic from non-arteritic AION is a combination of information from the following: systemic and visual symptoms of giant cell arteritis, high eryth rocyte sedimentation rate and C-reactive protein, early massive visual loss, chalky white optic disc swelling, associated cilio-retinal artery occlusion, massive non-filling of the choroid on fluorescein fundus angiography and temporal artery biopsy.
Management of giant cell arteritis and of arteritic AION is discussed. Current mis conceptions about AI ON are pointed out.
Anterior ischaemic optic neuropathy (AI ON)
is one of the most prevalent visually crippling diseases in the middle aged and elderly-a supply to this region. Usually there are two or three peAs arising from the ophthalmic artery, arranged medial and lateral to the optic nerve and designated as medial peA and lateral peA respectively.9,10 The peAs in vivo physiologically behave as end-arterieslO•11 and the watershed zone between the peAs may be situated anywhere between the fovea and the nasal border of the optic disc;6-8,10 the location of the watershed zone plays an important role in determining the site and extent of optic nerve head ischaemia.6-8 The blood supply of the anterior part of the optic nerve shows a marked inter-individual varia tion,6-8 which explains variation in the pattern of visual loss associated with AION in differ ent eyes, In many patients no definite cause can be discovered for the development of AION; however, the known causes of AION include giant cell arteritis (temporal or cranial arter itis)3, diabetes mellitus,12 arteriosclerosis, atherosclerosis, arterial hypertension, malig nant arterial hypertension,13 arterial hypotension, collagen vascular diseases, massive/ recurrent systemic haemorrhages,14 valvular heart disease, carotid artery disease, migraine, marked chronic optic disc oedema of any causelS and raised intraocular pres sure,16 with giant cell arteritis and diabetes mellitus as the most important causes.
From the aetiology and pathogenesis point of view, AION can usually be subdivided into two types: (i) due to thrombotic or embolic lesions of the peAs or their subdivisions, and (ii) due to temporary hypoperfusion or non perfusion of the nutrient vessels in the anterior part of the optic nerve, usually as a result of fall in the perfusion pressure in the peripapillary choroid; the second type of AION is by far the commonest variety. We have discussed the pathogenesis of AI ON , in generae,3,17,18 and in specific condi tions,12-16,19,20 in detail elsewhere. There is sudden, painless visual deterioration in one eye, usually discovered on waking in the morning. On examination, the visual acuity may vary from better than 6/6 to no light perception (Table) , 22 Perimetry usually reveals relative or absolute inferior altitudinal defect, inferior nasal sectoral defect or central scotoma, and less commonly other optic disc related field defects (Fig, 2) ,22 Fundus exam ination initially shows optic disc oedema, usually with splinter retinal haemorrhage(s) at the disc margin (Figs, 3, 4a, 5a, 6a, 7),3 .17, 23
The disc oedema usually resolves spontane ously in about two months and is replaced by sectoral or more often generalised optic atro phy, The fellow, normal optic disc shows either no cup or only a very small CUp,20
Fl uorescein angiography during the initial phase usually shows filling defects in the optic disc, peripapillary choroid and choroidal watershed zones (Figs, 4b, 5b) , and in giant cell arteritis much more extensive choroidal filling defects (Figs. 6b, C ) Fundus photograph of right eye with arteritic AlON, showing chalky-white swelling of the optic disc.
arteritic from non-arteritic AION almost invariably.
Systemic symptoms of giant cell arteritis
Typically the patient is sixty or older, more often female than male, and complains of vague aches and pains, malaise, anorexia, 'fiu'-like symptoms, weight loss, fever of unknown origin, headaches, scalp tender ness, neck pain, jaw claudication, anaemia or other vague systemic symptoms; the patient feels tired, sleepy and generally unwell. Paul ley and Hughes25 admirably summarised the symptoms when they stated that 'When elderly people begin to fail mentally and physically, this disorder should be one of the first to be considered'. We have seen many patients who have been subjected to exten sive, highly expensive and totally unnecessary systemic investigations to rule out malignan cies and other systemic causes for their symp toms and the missed diagnosis ultimately resulted in blindness. I find widespread lack of awareness among physicians of this impor tant, typical symptom-complex of giant cell arteritis. It is not at all uncommon in our experience to find patients who have repeat edly given a classical history of this disease to their physicians and yet the diagnosis was totally missed and the patient went blind in one or both eyes. However, not all patients with giant cell arteritis have systemic symp toms; in occult giant cell arteritis, the patient is perfectly fit and healthy and yet has classical evidence of giant cell arteritis. Tender, hard, nodular, prominent and non-pulsatile tempo ral arteries are described as a classical finding in these patients; however, perfectly normal and pulsatile temporal arteries are not uncommon in typical giant cell arteritis. These are some of the pitfalls, and it is impor tant to be aware of them.
Visual symptoms of giant cell arteritis
Amaurosis fugax is an important symptom of giant cell arteritis, because it is rarely noticed in non-arteritic AION. The presence of amaurosis fugax is an ominous sign of impending AION in patients with giant cell arteritis, and these eyes are at risk of develop-ing blindness very quickly. Typically, there is a sudden, painless, spontaneous and perman ent visual loss. A few patients may complain of diplopia. Some patients with giant cell arteritis are somewhat euphoric, so that in spite of bilateral total blindness, the patient may seem not to be very concerned about the visual loss and may even deny blindness.
3. High erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) These are two simple, quick, inexpensive and readily available tests. Although both tests are non-specific, levels are classically elevated in giant cell arteritis. If the ESR (as measured by Westergren method) is markedly elevated, e.g. about 80 mm or more, this is highly suggestive of giant cell arteritis; however, our experience has shown that the so-called 'normal ESR' in no way rules out this disease. This is because in our experience, 'normal ESR' varies from one to over 40 mm in the age-popUlation at risk of developing giant cell arteritis, and we could find no haematologic abnormality to explain such a wide variation. I have seen AION with active giant cell arteritis (confirmed on tem poral artery biopsy) where the ESR was S mm with the Westergren method. It is very impor tant to bear in mind that there is a tremendous variation in the normal levels of ESR in the elderly and this has not been adequately stressed in the literature, resulting in missing giant cell arteritis; ESR in the teens, twenties or even thirties has often been dismissed as 'normal'. This serious pitfall regarding ESR should be kept in mind.
For the past few years, in addition to ESR, we have used CRP to evaluate and manage these patients. A rise in CRP level in serum and other body fluids is produced by inflam matory processes in the body. 26 Usually changes in CRP correlate with the ESR; how ever, in some aspects it behaves differently from ESR. CRP does not rise during some viral diseases, some severe toxic states, and in some forms of chronic inflammatory arthri tis,27 when ESR does rise. Also, we have found much less fluctuation in CRP than in ESR. In our experience, combined infor mation from CRP and ESR is very useful in diagnosis and evaluation of patients with giant cell arteritis and in their follow-up on systemic corticosteroids. A normal CRP level (:::; 1 mg) with equivocal ESR strongly indicates absence of giant cell arteritis or good control with treatment, even when ESR is elevated; however, a markedly elevated CRP with so called 'normal ESR' would suggest giant cell arteritis. In some previous studies28 on CRP in giant cell arteritis, the results were given simply as 'positive' or 'negative' CRP and conclusions based on those could be mislead ing unless exact levels of CRP are given.
Early massive visual loss
In arteritic AI ON there is usually early mas sive visual loss, so that the eye has either no light perception or can barely see light or hand motion. In contrast to that in non-arteritic AION the visual loss is usually not so severe to begin with. Some time ago we analysed our data on the initial visual acuity in the two types of AION (Table) . 22 This revealed that in arteritic AION there was no light perception in 29%, hand motion or worse vision in 46%; on the other hand, in non-arteritic AION hand motion or worse vision was in only 9% . Thus, early massive visual loss is highly sug gestive of arteritic AION but normal visual acuity does not rule this out (Table). S. Chalky-white op tic disc swelling If the optic disc swelling is chalky-white initially (Fig. 7) , it is extremely suggestive of arteritic AION because this is exceedingly rare in non-arteritic AION.3,23 However, about 50% of eyes with arteritic AION do not show this and ophthalmoscopic disc appear ance is similar to that of non-arteritic AION (Fig. 3, 4a , Sa).
6. AlON associated with cilio-retinal artery occlusion In our experience, when optic disc oedema of AION is initially associated with cilio-retinal artery occlusion (Fig. 6) , it is almost always diagnostic of arteritic AION; I have yet to see this in a non-arteritic AI ON . 3,23 In giant cell arteritis the primary lesion responsible for AI ON is thrombotic occlusion of the PCA. If a PCA is occluded, it infarcts not only the area of the anterior optic nerve supplied by it ( Fig. 1) but also cuts out blood flow in the corresponding cilio-retinal artery. In contrast to that, our fluorescein fundus angiographic studies have consistently shown that non arteritic AION is almost always due to tran sient non-perfusion or hypoperfusion of the nutrient vessels in the anterior part of the optic nerve because of a fall in perfusion pres sure in the peripapillary choroid, and not due to peA occlusion6,17,21 (Fig. 4b, 5b) . In spite of my repeatedly stressing the latter fact over the years, I am constantly being misquoted by various authors as stating that non-arteritic AION is due to peA occlusion-this is simply not so in the vast majority of cases. That is why in non-arteritic AI ON there is no asso ciated occlusion of the cilio-retinal artery.
7.
Massive choroidal non-filling of the choroid on fluorescein fundus angiography If angiography is performed during the first days after the onset of arteritic AI ON , it almost always shows massive choroidal non filling, corresponding to the occluded peA (Fig. 6b, C) .3,6,17,21,23 This is almost always diagnostic of arteritic AION. In our experi ence the medial peA is involved much more frequently than the lateral peA by giant cell arteritis (Fig. 6b, c) . The area supplied by the medial peA shows a marked inter-individual variation, so that it may supply the entire nasal choroid up to the foveal region, includ ing the entire optic nerve head (Fig. 6b, c) , or it may stop short nasal to the medial peri papillary choroid so that the optic nerve head is supplied entirely by the lateral peA; or any variation between the two extremes.6-8 With the passage of time after the onset of arteritic AION, we have found that collateral circula tion in the choroid progressively results in fill ing of the involved choroid so that fluorescein angiography performed a week or more after the onset may not show any such massive fill ing defect. In non-arteritic AION, however, such massive choroidal non-filling is extremely rare. 6 Recently, Bosley et al. 29 described the role of ocular pneumoplethysmography in the diagnosis of giant cell arteritis. They studied nine patients with giant cell arteritis (with abnormal temporal artery biopsy) and visual loss (uniocular in seven and binocular in two). They stated that in giant cell arteritis ocular pulse amplitude and calculated ocular blood flow were reduced as compared to the normals and non-arteritic AION. This is not surprising; this is just another way to evaluate the peA occlusion caused by giant cell arter itis. However, unfortunately the authors did not perform fluorescein fundus angiography and provided no information on the state of the choroidal circulation on angiography in any of their patients. Four of the 11 eyes reported with visual loss in this series had cen tral retinal artery occlusion and the remaining seven had AION. In my anatomical studies I have shown that the central retinal artery and one or more peAs may arise by a common trunk from the ophthalmic artery in 60% of human cases.9,30 In giant cell arteritis patients, I have seen eyes which present with what, ophthalmoscopically, looks like central ret inal artery occlusion, but in fact, on fluores cein fundus angiography, turns out to have peA occlusion too, because of the thrombosis of their common trunk by giant cell arter itis. 3,23 It is well known that giant cell arteritis has a special predilection to involve peAs. Bosley et al. 29 reported that ocular pulse amplitude improved with the passage of time and (erroneously) attributed this to cortico steroid therapy; our fluorescein angiographic studies, in patients with arteritic AION and in rhesus monkey eyes after experimental peA occlusion, have consistently shown that the choroidal vascular bed in the involved area starts to fill progressively with the passage of time because of establishment of collateral circulationll which has nothing to do with corticosteroid therapy. Since ocular pneumo plethysmography essentially evaluates the choroidal circulation, other conditions caus ing choroidal insufficiency would give false positive results; the authors reported eight false positive results in non-arteritic AION. I find that fluorescein fundus angiography, a safe, routine and readily available test, usually gives much better and more detailed information on the peA, choroidal and optic disc circulations in giant cell arteritis than ocular pneumoplethysmography is likely to do. Moreover, there are some contraindi cations to doing ocular pneumoplethysmo graphy in persons of this age group.
Temporal artery biopsy
This must be performed in every patient having a high index suspicion of giant cell arteritis or of arteritic AIO N, to confirm and establish the diagnosis even though all other parameters may be classical of the disease. This mor phological documentation of giant cell arter itis is essential to justify committing a patient to protracted systemic steroid therapy, in view of the possible serious complications of such a long-term treatment and to safeguard against possible litigation emerging from such com plications. Temporal artery biopsy should be performed as soon as possible, but there is absolutely no justification to withhold systemic corticosteroid therapy until biopsy is done, because giving such treatment before the biopsy does not alter the outcome of the biopsy.
Since Birkhead et al. 31 in 1957 pointed out that involvement of the temporal artery by giant cell arteritis may be focal and segmental, the topic of 'skip lesions' in temporal artery in this disease has been raised from time to time. Cohen and Smith32 did not find any example of 'skip lesions' in their study of temporal artery biopsies from 42 patients. A number of studies, however, have shown the presence of 'skip areas , 33,34 strongly indicating that such areas do exist. This is obviously of great clini cal importance because examination of a 'skip area' alone, showing no granulomatous lesions, would give a false negative result and cause the physician to miss the diagnosis of giant cell arteritis. To minimise the risk of a false negative temporal artery biopsy and to diminish the chance of erroneous information from a 'skip area', our routine is to remove a long piece of the temporal artery and our pathologist serially sections it. He has dis covered skip areas located both circumfer entially and longitudinally but serial sectioning of a long segment of the artery removed at biopsy reduces markedly the danger of a false negative biopsy. Studies by Wells et at. 35 from our Department have shown that direct immunofluorescence micro scopy of temporal artery biopsy sections is not more sensitive or specific than light micro scopy, thus they questioned its routine use as a diagnostic test. In a rare case, however, they found immunofluorescence microscopy iden tified temporal arteritis despite negative find ings by light microscopy. In patients with a strong clinical suspicion for giant cell arteritis we biopsy the second side if one side shows no granulomatous lesion. Biode6 found no case of false negative biopsy in his series. Hedges et at. 37 found it in 5% of their cases, and Hall et at.38 in 6%. In my experience in our clinic, I saw four such patients during the early stages of our study who met all the remaining criteria for arteritic AI ON mentioned above, and whose therapeutic response and follow-up course was exactly like giant cell arteritis, but who had a negative biopsy on both sides; at that time we were not very particular about removing a large piece of the temporal artery and doing serial sectioning. The high inci dence of false negative temporal artery biopsy reported in some of the papers in the liter ature may be due either to removing only a small segment of the artery, not examining the entire piece by serial sectioning, or problems in defining giant cell arteritis cases in the first place. Thus, I feel temporal artery biopsy, if done properly and examined correctly, has the highest sensitivity and specificity for detection of giant cell arteritis.
Conclusions
Our experience shows that none of the para meters mentioned above has 100% reliability in differentiating arteritic AI ON from non arteritic AION. Sometimes there are false negative or even false positive findings. Com bined information from all the parameters, however, helps make such a differentiation in almost all cases.
(B) Management of Arteritic AION and
Giant Cell Arteritis
There is universal agreement that arteritic AI ON should be treated with systemic corticosteroids as an emergency, to prevent any further visual loss. However, there is a good deal of controversy and variation in the literature in the therapeutic regimen advo cated in these cases. I shall describe here only what is our practice, which has evolved from my experience of dealing with the disease for the past 20 years. If there is a reasonable index of suspicion that the patient has giant cell arteritis, with or without visual loss, we start the patient on systemic corticosteroids immediately as a prophylaxis, even before doing temporal artery biopsy or getting its results. This is important; it may be unsafe to wait till the biopsy diagnosis is available, since the patient could further lose vision during this interval. If the temporal artery biopsy result and other evidence indicates that there is no giant cell arteritis, the drug can be stopped. The dosage and mode of its administration depends upon the severity of visual loss and systemic mani festations. If a patient presents with no visual symptoms or visual loss, we start with at least 80 mg of oral prednisone daily or even up to 120 mg, depending upon the severity of systemic symptoms, ESR and CRP. We do, however, give megadose corticosteroid ther apy intravenously to start with on an emer gency basis when a patient with symptoms of giant cell arteritis has any one of the following ocular signs or symptoms: (i) visual symptoms (particularly amaurosis fugax), (ii) a complete loss of vision in one eye, or (iii) early evidence of second eye involvement (amaurosis fugax, visual field defect, optic disc oedema, cilio retinal artery occlusion, or sluggish circula tion in the central retinal artery). Our mega dose therapy consists of giving usually the equivalent of one gram of prednisone slowly by intravenous drip, every 6-8 hours and 3-4 such doses. This is followed by 120 mg pred nisone orally daily. We estimate ESR and CRP daily initially to evaluate the response of the patient to the therapy. ESR and CRP initially show a rapid drop-the response varies a good deal in different patients. We keep the patient on the high doses of pred nisone till the marked and rapid initial fall in ESR and CRP changes to a mild downfall (Fig. 8) ; following this we slowly start to taper down the dosage of prednisone in steps of about 10 mg every 3-4 days. The response is judged by repeated ESR and CRP, at least once a week till the dosage is about 60 mg daily. No generalisation is possible, because of the wide variation in response by different patients to the treatment from this point on. Some patients respond dramatically, and one can go down with the prednisone dosage faster than in others who respond very slowly. I have seen some patients in whom any reduc tion of dosage to less than 80 mg results in a rise of ESR and CRP, and one has no option but to stall at that dosage for a much longer time than usual.
Determination of the maintenance dose is a slow, laborious and painstaking job over many months. The guiding principle in deter mining the dosage is to titrate the dosage of prednisone with the levels of ESR and CRP, the object being to have the lowest levels of ESR and CRP with the lowest level of pred nisone. There is no formula or any other way to predict the maintenance dosage required by a particular patient; it is only by trial and error that one can determine this. Once a maintenance dosage is established, the patient is followed much less frequently while on that dose. Our experience of following these patients for up to 15 years has shown that they require maintenance dosage for years-the concept that giant cell arteritis burns itself out after about 9-12 months is not at all true and is based more on clinical impression than on any valid scientific data.
Alternate-day corticosteroid therapy is fre quently advocated and even practised for the management of giant cell arteritis. I find that there is a good deal of misunderstanding of this therapy. Fauci39 has reviewed the subject admirably. He rightly stated that 'The primary goal in the clinical use of corticosteroids' 'is to balance maximal therapeutic efficacy with a minimum of deleterious side effects.' Accord ing to him, alternate-day corticosteroid ther apy 'will not interfere with the normal ACTH-cortisol cycle, nor will it expose the tissues to sustained levels of hormone throughout the day'. However, the question arises whether such a regimen can effectively control active inflammatory process such as in giant cell arteritis? Fauci3Y states that 'it is quite difficult, if not impossible, to satisfac torily induce a remission with alternate-day corticosteroid therapy in a fulminant or grossly active disease'. All the available evi dence seems to indicate that such a regimen has no place in management of active giant cell arteritis. Obviously the next question is whether such a therapy can maintain suppres sion of inactive giant cell arteritis? Av ailable evidence once again seems to indicate that this is most probably not possible. Moreover, the foremost tactical issue is converting from daily to alternate-day therapy. One cannot do it immediately. Fauci39 advocates that in such a conversion, one should immediately double the dose on the 'on' days, preferably as a single morning dose, and the dose on the 'off' days is then gradually tapered off. He advises close supervision of the patient during this conversion phase because of the risk of flare-up of inflammatory process. According to him 'the process of conversion may be diffi cult, at times discouraging and, in some cases, impossible'. I hope this places the alternate day steroid therapy in its true perspective and eliminates all the misunderstandings about it. We have not used alternate-day therapy.
The objectives of corticosteroid therapy: In the management of these patients with giant cell arteritis, we have found it helpful to explain at length at the very beginning the fol lowing objects of treatment: (1) The principal object of the treatment is to prevent blindness. Our experience indicates that during the first week of the therapy one should give a guarded prognosis about any further visual loss because we have found that about 5% of patients during this period, in spite of the aggressive treatment and even mega dose intravenous corticosteroid therapy, did suffer further loss of vision, even complete blindness, but none after that. We, therefore, feel that one can virtually guarantee that if a person does not suffer any further visual loss for one week after starting treatment with the high doses suggested above, the chance of visual loss after that is practically none. This is proof of the effectiveness of adequate systemic corticosteroid therapy in the preven tion of visual loss in giant cell arteritis. (2) It has been claimed by some authors, from time to time, that aggressive treatment with systemic corticosteroids can restore visual loss in arteritic AlaN. Our experience does not support this view at all, because, on the whole, we have not seen any worthwhile visual recovery in spite of early, aggressive, megadose steroid therapy. Only a very rare patient has shown some visual improvement. I have frequently found that patients have the impression that aggressive steroid therapy is really meant to reverse their visual loss. To avoid serious disappointment, it is essential to stress at the outset that the object of the treat ment is not to recover the lost vision but to prevent any further visual loss-if the patient is not aware of this fact, he/she is likely to co operate poorly with continued treatment and thereby to risk losing further vision. (3) The most important point to stress is that the treatment is essentially suppressive and not curative, and will be required for years to prevent any further visual loss. This infor mation is vital for regular compliance of the treatment, without any break and as directed. At the same time it is essential to discuss in detail the various complications of prolonged steroid therapy and how to avoid some of them or manage them, so that the patient is not only aware of those but also emotionally and physically prepared for them. It is also vital to involve their local physician in moni toring and management of systemic side effects of corticosteroid therapy.
I have found that most ophthalmologists and physicians have either distorted or inade quate information on the management of patients with giant cell arteritis, with or with out visual loss. The management of this disease is very taxing both for the patient and for the physician.
Unfortunately, we have no effective and well-established therapy for non-arteritic AION-either for visual recovery or for prophylaxis against the involvement of the second eye, the incidence of which is quite high, particularly in diabetics. 19 
(C) Misconceptions about AI ON
A number of serious misconceptions have developed over the years about AION, and these are responsible for misdiagnosis of AION and consequent unnecessary and expensive investigation in those patients. It is important to comment briefly on these mis conceptions, which include the following:
1. AION is exclusively a disease of the elderly This is because it is assumed that ischaemic disorders do not occur in young persons. Based on this misconception, in the previous studies on AION reported in the literature, patients younger than 50 or so were excluded from the studies so that AION in those cases was instead diagnosed as optic neuritis. We have found that AION is a disease of all ages and no age is immune from it.
2. Eyes with AION must be blind or almost blind In our studies in non-arteritic AION, 41 % of the eyes had 6112 or better visual acuity (26% had 6/6) and 63% had 6/30 or better (Table) . Even in arteritic AION, the visual acuity was 6112 or better in 26% (14% had 6/6) and 40% had 6/24 or better (Table) 22. Thus, these eyes do not have to be stone blind.
3. AION always has pale optic disc oedema Our experience has shown that during the very early stages, optic disc oedema in non arteritic AION on ophthalmoscopy may look no different from any other type of optic disc oedema, and the disc may be even hyper aemic. It is only after a couple of weeks or so that the disc starts to show pallor with oedema. Presumably this misconception crept in because the published reports have been from referral centres where the patients were usually not seen early enough. In our series, about half of the eyes with arteritic AION even showed a pattern similar to that seen in non-arteritic AION, and only about half of the eyes with arteritic AION really showed pale oedema of the disc from the very start.
4. Asymptomatic optic disc oedema is not seen in AION My studies18 have shown conclusively that asymptomatic optic disc oedema may precede the visual loss in AION. I have collected over 25 such cases over the years.
5.
Neural ischaemia is an 'all or none' phenomenon It is well-known that neural ischaemia can vary from sub-clinical to an extreme type. Consequently, the ischaemic damage to the optic nerve head can vary from sub-clinical18 to total infarction and the clinical manifesta tions would differ accordingly. 
